Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).

Inclusion Criteria:

1. Men and Women with Metabolic Syndrome
2. Elevated Triglycerides (> 150)
3. Low High-Density Lipoprotein (HDL) (< 35)
4. Willingness to take study nutritional supplement once a day for 3 months

Exclusion Criteria:

1. Women who are pregnant, nursing, or who intend pregnancy during the period of treatment
2. Known milk, soy or whey allergy